• 1
    Zeliadt SB, Moinpour CM, Blough DK, et al. Preliminary treatment considerations among men with newly diagnosed prostate cancer [serial online]. Am J Manag Care. 2010;16:e121-e130.
  • 2
    Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose 1 treatment over another? A review of patient decision making for localized prostate cancer. Cancer. 2006;106:1865-1874.
  • 3
    Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med. 2000;15:694-701.
  • 4
    Feldman-Stewart D, Brundage MD, Van Manen L, Svenson O. Patient-focused decision-making in early-stage prostate cancer: insights from a cognitively based decision aid. Health Expect. 2004;7:126-141.
  • 5
    Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-1261.
  • 6
    Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009;101:888-892.
  • 7
    Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436-445.
  • 8
    Johansson E, Steineck G, Holmberg L, et al. for the SPCG-4 Investigators. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011:12;891-899.
  • 9
    Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306:1205-1214.
  • 10
    Freedman, DS; Centers for Disease Control and Prevention (CDC), Obesity—United States, 1988-2008. MMWR Surveill Summ. 2011;60(suppl):73-77.
  • 11
    Geiss, LS, Li, Y, Kirtland, K, et al. Centers for Disease Control and Prevention (CDC). Increasing prevalence of diagnosed diabetes–United States and Puerto Rico, 1995-2010. MMWR Morbidity and Mortality Weekly Reports. 2012;61:918-921.
  • 12
    Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol. 2004;171:2341-2345.
  • 13
    Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ; Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006;166:207-212.
  • 14
    Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996;48:773-777.
  • 15
    Barocas DA, Chen V, Cooperberg M, et al. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013;2:445-460.
  • 16
    Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899-905.
  • 17
    Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245-1250.
  • 18
    Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the Total Illness Burden Index for Prostate Cancer: aiding clinicians in treatment choice. Cancer. 2007;109:1777-1783.
  • 19
    Markland AD, Richter HE, Fwu C-W, Eggers P, Kusek JW. Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol. 2011;186:589-593.
  • 20
    Litwin MS. Health related quality of life in older men without prostate cancer. J Urol. 1999;161:1180-1184.
  • 21
    Erickson BA, Vaughan-Sarrazin M, Liu X, Breyer BN, Kreder KJ, Cram P. Lower urinary tract symptoms and diet quality: findings from the 2000-2001 National Health and Nutrition Examination Survey. Urology. 2012;79:1262-1267.
  • 22
    Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol. 1999;17:2882-2888.
  • 23
    Fransson P, Damber J-E, Widmark A. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer. Scand J Urol Nephrol. 2009;43:119-126.
  • 24
    Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL. Validation study of retrospective recall of disease-targeted function: results from the Prostate Cancer Outcomes Study. Med Care. 2000;38:847-857.
  • 25
    Wilt TJ, Brawer MK, Jones KM, et al. Prostate Cancer Intervention Versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-213.
  • 26
    Bill-Axelson A, Holmberg L, Ruutu M, et al. SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708-1717.
  • 27
    Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81-87.
  • 28
    Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993;20:557-560.
  • 29
    Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592.